News for SELLAS Life Sciences Group Stock (SLS)

SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia

GlobeNewsWire • 12/04/23

SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia

GlobeNewsWire • 11/29/23

SELLAS Life Sciences Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls (CMC) Biologics License Application (BLA) Filing Strategy for Galinpepimut-S (GPS)

GlobeNewsWire • 11/13/23

SELLAS Life Sciences Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting

GlobeNewsWire • 11/06/23

SELLAS Life Sciences Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewsWire • 10/31/23

SELLAS Life Sciences Receives Fast Track Designation from FDA for SLS009 for Treatment of Relapsed/Refractory Peripheral T-cell Lymphomas

GlobeNewsWire • 10/30/23

SELLAS Life Sciences to Present Final Data from Phase 1/2 Study of Galinpepimut-S in Combination with Keytruda® (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting

GlobeNewsWire • 10/17/23

SELLAS Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia

GlobeNewsWire • 10/16/23

SELLAS Life Sciences Provides Update on Phase 3 REGAL Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia

GlobeNewsWire • 10/12/23

SELLAS Advances Blood Cancer Treatment with “Tremendous Therapeutic Promise”

MCAP MediaWire • 10/11/23

SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell Lymphomas

GlobeNewsWire • 10/11/23

SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Acute Myeloid Leukemia

GlobeNewsWire • 10/10/23

SELLAS SLS009 Phase 1 Clinical Study Successfully Achieves All Primary and Secondary Endpoints

MCAP MediaWire • 09/22/23

SELLAS Announces Positive Topline Data in Lymphoma Cohort from SLS009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met

GlobeNewsWire • 09/21/23

SELLAS Life Sciences to Participate in the Cantor Fitzgerald Global Healthcare Conference

GlobeNewsWire • 09/18/23

SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue Without any Modifications

GlobeNewsWire • 08/22/23

SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results

GlobeNewsWire • 08/10/23

SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

GlobeNewsWire • 06/28/23

SELLAS Announces First Patient Dosed in Phase 2a Clinical Trial of GFH009 in Acute Myeloid Leukemia

GlobeNewsWire • 06/22/23

SELLAS Life Sciences Announces Abstract Accepted for Presentation at International Gynecologic Cancer Society Annual Meeting

GlobeNewsWire • 06/15/23

SELLAS to Participate in Maxim Group Healthcare Virtual Conference

GlobeNewsWire • 06/13/23

SELLAS Life Sciences to Present Phase 3 REGAL Trial in Progress Poster at 2023 ASCO Annual Meeting

GlobeNewsWire • 05/25/23

SELLAS Life Sciences to Host Virtual Expert Panel Discussion on GFH009 in Acute Myeloid Leukemia

GlobeNewsWire • 05/16/23

SELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Results

GlobeNewsWire • 05/11/23

SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting

GlobeNewsWire • 04/26/23